A phase open-label, dose-escalation study of the safety and pharmacokinetics of apomab administered intravenously to subjects with advanced or metastatic solid malignancies, or non-Hodgkin's lymphoma
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2006
At a glance
- Drugs Drozitumab (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Biomarker
- 01 Aug 2006 New trial record.